ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2411

C-X-C Motif Chemokine Receptor 4-targeted Molecular Imaging in Giant Cell Arteritis – a Head-to-head Comparison with FDG PET

Matthias Froehlich1, Sebastian E. Serfling2, Michael Gernert3, Konstanze V. Guggenberger4, Takahiro Higuchi2, Samuel Samnick2, Marc Schmalzing5, Andreas K. Buck2, Thorsten Bley4 and Rudolf A. Werner2, 1Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Würzburg, Würzburg, Germany, 2Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany, 3Medical Department II, Rheumatology, University Hospital Würzburg, Würzburg, Germany, 4Institute of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, Germany, 5University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany

Meeting: ACR Convergence 2023

Keywords: giant cell arteritis, Imaging, Nuclear Medicine

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: 2-[18F]fluoro-2-deoxy-D-glucose(FDG) is the reference PET radiotracer for detecting inflammation in giant cell arteritis (GCA). C-X-C motif chemokine receptor 4 (CXCR4)-directed PET, however, allows for targeting leukocyte subsets, thereby providing a direct visualization of active inflammation. We aimed to report initial results from a Phase II trial applying chemokine receptor-targeted imaging in patients with newly diagnosed GCA (NCT05604482).

Methods: Nine treatment-naïve individuals with confirmed GCA underwent PET/CT imaging with both FDG and [68Ga] PentixaFor (PXF). For each PET, a total of 13 arterial segments per patient were analyzed. In addition, eight joints were examined for concurrent polymyalgia rheumatica. We compared both scans on a visual (using PETVAS) and quantitative level (by calculating the target-to-background ratio [TBR], with blood pool as reference). Flow cytometry determined quantitative CXCR4 expression on leukocytes in peripheral blood by calculating a normalized median fluorescence intensity (NMFI) scoring (with CXCR4 antibody isotype serving as control). Quantitative PET results were then correlated with NMFI.

Results: At the visual level, PETVAS of FDG (25.62 ± 5.61) was comparable with PXF (21.33 ± 3.5, P=0.07). The TBR of FDG (2.41 ± 0.96) was also not significantly different from that of PXF (1.8 ± 0.8, P=0.11). The interquartile ranges (IQR) for PEN (IQR, 0.48), however, were lower than for FDG (IQR, 1.5), suggesting lower scatter and improved accuracy for PXF-based quantitative read-outs. Comparable results were also recorded for joints (PEN: IQR, 0.25; FDG: IQR, 0.5). Flow cytometry showed broad expression of CXCR4 on leukocytes. Subpopulations with the highest CXCR4 expression were naive B and T cells, followed by basophils. NMFI and PXF-based quantification showed significant correlations with basophils in the aorta, with the most prominent association for the abdominal segment (r=0.85, P=0.03).

Conclusion: Quantification of the CXCR4-targeted PET radiotracer PXF was comparable to FDG for assessing vessel wall and joint inflammation. Thus, PXF PET may be incorporated for image-guided, anti-inflammatory strategies in patients with newly diagnosed GCA.


Disclosures: M. Froehlich: None; S. Serfling: None; M. Gernert: None; K. Guggenberger: None; T. Higuchi: None; S. Samnick: None; M. Schmalzing: AbbVie, 2, 6, Boehringer Ingelheim, 2, 5, 6, Chugai/Roche, 2, EUSA-Pharma, 2, 6, Galapagos, 2, 5, 6, Hexal/Sandoz, 2, Janssen-Cilag, 2, 6, Lilly, 2, onkowissen.de, 2, UCB, 2, 5; A. Buck: None; T. Bley: None; R. Werner: None.

To cite this abstract in AMA style:

Froehlich M, Serfling S, Gernert M, Guggenberger K, Higuchi T, Samnick S, Schmalzing M, Buck A, Bley T, Werner R. C-X-C Motif Chemokine Receptor 4-targeted Molecular Imaging in Giant Cell Arteritis – a Head-to-head Comparison with FDG PET [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/c-x-c-motif-chemokine-receptor-4-targeted-molecular-imaging-in-giant-cell-arteritis-a-head-to-head-comparison-with-fdg-pet/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/c-x-c-motif-chemokine-receptor-4-targeted-molecular-imaging-in-giant-cell-arteritis-a-head-to-head-comparison-with-fdg-pet/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology